Viewing Study NCT07426757


Ignite Creation Date: 2026-03-26 @ 3:16 PM
Ignite Modification Date: 2026-03-30 @ 2:37 AM
Study NCT ID: NCT07426757
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-12
First Post: 2026-02-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Sponsor: Pfizer
Organization:

Study Overview

Official Title: An Open-Label Phase 1 Study to Evaluate PF-07994525 in Participants With Advanced Malignancies
Status: NOT_YET_RECRUITING
Status Verified Date: 2026-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.

The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
KAT2i OTHER Alias Study Number View